petrospharma.com - PTPI Company profit before taxes, interest and amortization
Petros Pharmaceuticals is implementing zero-waste synthesis and strict chemical disposal controls. Despite patent protection, Petros Pharmaceuticals faces pressure from low-cost generics and the expansion of telemedicine. Developments in men's health rely on digital services and improved bioavailability of formulas. EBITDA dynamics demonstrate the efficiency of converting revenue into cash, where the value describes the current level of operating profit.
Summary analytical data breakdowns for Petros Pharmaceuticals, Inc. (PTPI)
- market value and analyst target forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Petros Pharmaceuticals|PTPI - Long-Term Debt to Equity|Current Liabilities to Equity Petros Pharmaceuticals Inc|PTPI - Company Aggregate Debts|Debts to Book Value Petros Pharmaceuticals|PTPI - Company Long-Term Liabilities|Amount of Current Liabilities Petros Pharmaceuticals|Intermediate Coverage Ratio petrospharma.com
- earnings and market ratios statistics:
PTPI - Company Net Income|Expected Net Profit Petros Pharmaceuticals|PTPI - Price to Earnings Ratio|Market Cap to Projected Earnings petrospharma.com|PTPI - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Petros Pharmaceuticals|PTPI - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Petros Pharmaceuticals|PTPI - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months petrospharma.com|PTPI - Earnings growth in current year|Earnings growth forecast for next year Petros Pharmaceuticals
- sales revenue and business income indicators:
Summary company analytics:Petros Pharmaceuticals
The Petros Pharmaceuticals outsourcing model minimizes capital expenditures by delegating production, converting licensing revenues into pure cash flow. This metric aggregates operating profit before interest and taxes to measure internal cash generation efficiency, allowing investors to assess the real rate of capital growth based on actual EBITDA.
Competitor analysis for Petros Pharmaceuticals
Haleon Corp (HLN) - Profit before interest, taxes and amortization|KVUE: Operating profit before deduction of amortization|veronapharma.com - Company profit before taxes, interest and amortization|MENS: Operating profit EBITDA|Ligand Pharmaceuticals Incorporated - Income before deduction of interest, taxes and amortization|AMRX (Amneal Pharmaceuticals Inc) - Operating profit EBITDA|Profit before interest, taxes and amortization Perrigo Corp PRGO|Profit before payment of interest, taxes and amortization Alvotech (ALVO)|LQDA (liquidia.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Galapagos GLPG|ANIP (ANI Pharmaceuticals Inc) - Profit before deduction of interest, taxes, depreciation and amortization|MannKind Corp. - Operating profit EBITDA|Profit before interest, taxes and amortization Amphastar Corp|PCRX (Pacira BioSciences) - Operating profit before deduction of amortization|SPRY: Company profit before taxes, interest and amortization|Profit before payment of interest, taxes and amortization Theravance Biopharma, Inc.|AQST: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization scPharmaceuticals Inc. (SCPH)|TECX - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Tonix Pharmaceuticals TNXP|Operating income before deduction of amortization SXT Pharmaceuticals (SXTC)|EPRX: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization BHST (BioHarvest Sciences, Inc.)|Invizyne Technologies, Inc. (EXOZ) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization ORMP (Oramed Pharmaceuticals Inc.)|ENTX (Entera Bio Ltd) - Operating profit EBITDA|HYFT: Income before deduction of interest, taxes and amortization|Operating profit EBITDA ABVC|Operating profit EBITDA Cumberland Pharmaceuticals Inc (CPIX)|Profit before payment of interest, taxes and amortization Quantum BioPharma Limited QNTM|Income before deduction of interest, taxes and amortization FGEN|TELO - Profit before payment of interest, taxes and amortization|Rani Therapeutics (RANI) - Operating profit before deduction of amortization|SNYR: Operating profit EBITDA|Rallybio (RLYB) - Operating profit EBITDA|LEXX (Lexaria Bioscience Corp) - Operating profit EBITDA|Operating profit before deduction of amortization Pulmatrix Corporation (PULM)|Operating profit EBITDA PTHL|APM - Profit before interest, taxes and amortization|Lyra Therapeutics - Operating profit before deduction of amortization|Operating profit EBITDA Impact BioMedical, Inc. IBO|TNFA: Operating profit before deduction of amortization|cbdMD, Inc. - Company profit before taxes, interest and amortization|PRFX: Operating profit EBITDA|CYTO - Operating income before deduction of amortization|LIPO (Lipella Pharmaceuticals, Inc.) - Operating profit EBITDA|Operating profit before deduction of amortization OptiNose Inc (OPTN)|Operating profit EBITDA PIRS|Operating profit EBITDA Procaps Group Corp (PROC)|Profit before payment of interest, taxes and amortization Qilian International QLI|acelyrin.com - Profit before payment of interest, taxes and amortization|TFFP - Profit before payment of interest, taxes and amortization
